Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,393
Out of 5,114 analysts
53
Total ratings
30%
Success rate
6.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $17.72 | +317.61% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $6.41 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $68.26 | +28.92% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $15.40 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $44.92 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $72.57 | +32.29% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.06 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.38 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $26.84 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $16.91 | -23.06% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.76 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $53.35 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $101.08 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.61 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.67 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.00 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $176.18 | +65.74% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $475.68 | -22.22% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.06 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.55 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $17.72
Upside: +317.61%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $6.41
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $68.26
Upside: +28.92%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.40
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $44.92
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $72.57
Upside: +32.29%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.06
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.38
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.84
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $16.91
Upside: -23.06%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.76
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $53.35
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $101.08
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.61
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.67
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $176.18
Upside: +65.74%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $475.68
Upside: -22.22%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.06
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -